[Five experts interviewed about drugs. Benefits for the patients could have been more emphasized].
Melander
Arne
A
Stiftelsen NEPI, Nätverk för läkemedelsepidemiologi, Malmö och Stockholm. arne.melander@nepi.net
D017046:Cost Savings; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D011307:Drug Prescriptions / Q000191:economics; D004363:Drug Utilization / Q000191:economics; D006801:Humans; D010349:Patient Compliance; D019338:Polypharmacy; D013548:Sweden; D016896:Treatment Outcome